Authorization

Axsome Shares Shoot Higher As FDA Approves Major Depressive Disorder Candidate

Axsome Shares Shoot Higher As FDA Approves Major Depressive Disorder Candidate
The U.S. Food and Drug Administration (FDA) has approved Axsome Therapeuticsa?? (NASDAQ:AXSM) lead asset AUVELITY (dextromethorphan HBr -bupropion HCl) extended-release tablets for the treatment of major depressive disorder (MDD) in adults.

The AUVELITY New Drug Application (NDA) was evaluated by the agency under Priority Review.

The lead drug was studied in a comprehensive clinical program which included more than 1,100 patients with depression.

The regulatory approval is supported by the efficacy of AUVELITY in the treatment of MDD, demonstrated in the GEMINI placebo-controlled study, and confirmatory evidence which included the ASCEND study comparing AUVELITY to bupropion sustained-release tablets.

Herriot Tabuteau, Chief Executive Officer, commented: "The approval of Auvelity is the culmination of the tremendous and focused research and development activities conducted by the Axsome team and our collaborators. We are extremely proud to deliver this Breakthrough Therapy-designated new treatment to the millions of patients living with depression at a time when it is most needed, given the recent sharp increase in depression prevalence.a??
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Январь 2023    »
ПнВтСрЧтПтСбВс
 1
2345678
9101112131415
16171819202122
23242526272829
3031